Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug Switching Strategy Study After rhTPO Second-Line Treatment Failure in ITP
NCT07476846Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- Cytokines & Interferons
01
Overview
Randomised, open-label trial in immune thrombocytopenia (ITP) comparing rhTPO Double-Dose Group with EPAG-pfos Group (2 arms). Primary endpoint: Platelet Response Rate (RR) at 6 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
recombinant human thrombopoietineltrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07476846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07476846.